港股異動 | 希瑪眼科(3309.HK)跌近5% 料中期業績盈轉虧
格隆匯8月10日丨希瑪眼科(3309.HK)現報6.32港元,跌4.96%,暫成交3325萬港元,最新總市值72億港元。希瑪眼科上週五(7日)晚間發公告稱,預期中期將錄得淨虧損,金額範圍介乎1500萬港元至2500萬港元,而去年同期則錄得淨利潤約3310萬港元。預虧的主要原因是2019新冠病毒疫情所導致的影響。期間,集團於內地的醫院於今年首季度曾關閉長達六週;此外,北京於6月爆發第二波疫情,令集團位於北京的業務進一步受挫。集團在內地及香港的業務的營運情況正從疫情的影響下逐步恢復。未來營運表現將取決於疫情能否得到較好控制以及經濟活動放緩的程度。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.